Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390518 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
A Phase 1 study of Brain Metastases, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02390518 is a Phase 1 study of Brain Metastases that is actively recruiting participants, run by University of Utah. The registered enrollment target is 50 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02390518, a Phase 1 study of Brain Metastases, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received radiation to the brain before.
Conditions Studied
Interventions
- RADIATION Stereotactic Radiosurgery
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-05-07 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390518
The ClinicalTrials.gov registry entry for NCT02390518 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (76% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Radiosurgery is the first listed.
NCT02390518 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT02390518 about?
NCT02390518 is a clinical study titled "Stereotactic Radiosurgery Dose Escalation for Brain Metastases". This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received radiation to the brain before.
What is the current status of trial NCT02390518?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-05-07. Estimated completion is 2026-04.
What conditions does trial NCT02390518 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02390518?
The interventions under investigation include: Stereotactic Radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT02390518?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02390518 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RECRUITING · Phase 1
-
Phase I Study of Fractionated Stereotactic Radiation Therapy
RECRUITING · Phase 1
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.